Meeting News CoverageVideo

VIDEO: CPX-351 improves outcomes for elderly patients with high-risk AML

CHICAGO — Aref Al-Kali, MD, assistant professor of medicine at Mayo Clinic in Rochester, Minnesota, highlights results from a randomized phase 3 trial that evaluated the use of CPX-351 in elderly patients with high-risk acute myeloid leukemia at the ASCO Annual Meeting.

Results showed that compared with standard “7 + 3” chemotherapy (cytarabine and daunorubicin), CPX-351 (Vyxeos, Celator) induced better response rates and prolonged OS and RFS.

“This study is a very important study as it might change the way oncologists and hematologists practice,” Al-Kali said. “What is also interesting is that this drug showed less mortality in the first 1 and 2 months, as this drug seems to be better tolerated by patients.”

CHICAGO — Aref Al-Kali, MD, assistant professor of medicine at Mayo Clinic in Rochester, Minnesota, highlights results from a randomized phase 3 trial that evaluated the use of CPX-351 in elderly patients with high-risk acute myeloid leukemia at the ASCO Annual Meeting.

Results showed that compared with standard “7 + 3” chemotherapy (cytarabine and daunorubicin), CPX-351 (Vyxeos, Celator) induced better response rates and prolonged OS and RFS.

“This study is a very important study as it might change the way oncologists and hematologists practice,” Al-Kali said. “What is also interesting is that this drug showed less mortality in the first 1 and 2 months, as this drug seems to be better tolerated by patients.”

    See more from ASCO Annual Meeting